Please note that maintenance work is scheduled between 4 AM and 5 AM - CET.
During this time, you may experience reduced performance.
Thanks for your patience.
in (world ranking)
Emmanuel Gyan
Joined Jul 2026
Centre Hospitalier Universitaire de Tours · Hematology
Top 1% Worldwide expert in Epcoritamab, Lymphoma, Lymphoproliferative Disorders, Leukemia
Emmanuel Gyan is an expert in Hematology at Centre Hospitalier Universitaire de Tours (France). As of September 2026, ScienceLeadR ranks Emmanuel Gyan in the top 1% of experts worldwide for Lymphoma, Lymphoproliferative Disorders and Leukemia. Emmanuel Gyan has authored 405 publications, the most recent in 2026, and is an investigator in 66 clinical trials, 23 of them ongoing. SLR score: 1,700 (community average: 125). How the SLR is computed.
POSITION
Since September 2014, I am professor in hematology at the Faculty of Medicine of Tours, France, and the head of department of the hematology and cell therapy unit.
CLINICAL RESEARCH
I am coordinator of several clinical studies at the national level, in the LYSA and the FILO collaborative groups:
Identification of Trial ClincalTrials.gov Phase Role in Trial Year
BRIEF protocol (LYSA) NCT01313611 II Coordinating investigator 2011-2012
FAMYLY protocol (GOELAMS) NCT01999413 II Coordinating investigator 2012-2014
R-NIMP Protocol (GOELAMS) NCT00842595 II Coordinating Investigator 2003-2008
At the hospital level, I am the medical coordinator of the clinical research platform, and responsible for the enhancement of early phase clinical research activity. In this perspective, together with the research administration of the university hospital, we have organized the phase I activity in à dedicated unit, and a study nurse on-duty list for week-end and night PK sampling.
REGIONAL ORGANIZATION OF HEMATOLOGY
Since my arrival un the Centre region in 2006, I have continued the work of my mentor Philippe Colombat, who created a regional network of physicians involved in hematology patient care. We organize two annual meetings and videoconferencing for difficult hematology cases.
SUPPORTIVE CARE
I have contributed to the creation of talking groups for children of patients fighting cancer.
ONGOING PROJECT
We are in the process of building an extension to the hematology department in order to be able to treat all the leukemias and allogeneic transplantations for patients of the region.
OASIS II A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma 2024-512634-15-00 — cells, lymphoma, lymphoma, mantle-cell
Phase 1/Phase 2
Active not recruiting
2022
A clinical trial of MK 1045 and rituximab in people with follicular lymphoma (MK 1045 007) 2025-522777-10-00 — lymphoma, follicular, lymphoma, respect, rituximab, physicians
Phase 2/Phase 3
Recruiting
2026
A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Patients with Relapsed Refractory Aggressive B Cell Non Hodgkin s Lymphoma 2024-516791-15-00 — cytokines, cells, hodgkin disease, lymphoma, oxaliplatin, cytokine release syndrome, lymphoma, non-hodgkin, b-lymphocytes
Phase 2
Active not recruiting
2025
1L LUSPA VS ESA IN NTD LOW RISK MDS PATIENTS 2022-500430-29-00 — epoetin alfa, myelodysplastic syndromes, safety, anemia, therapeutics, erythropoiesis
Phase 3
Active not recruiting
2023
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma 2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics
To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawal of consent may adversely affect certain features and functions.
Functional
Always active
Storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of transmitting a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
Storage or technical access used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles in order to send advertisements, or to track the user on a website or on several websites with similar marketing purposes.